30
300759.SHE Pharmaron Beijing Co Ltd
- Market cap
- CNY 75.5B
- P/E
- 40.7x
- P/B
- 4.50x
- ROE
- 9.8%
- Dividend yield
- 0.70%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300759.SHE undervalued?
Graham number300759.SHE trades 185.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pharmaron Beijing Co Ltd fundamental analysis
No fundamental analysis for Pharmaron Beijing Co Ltd yet.
Pharmaron Beijing Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pharmaron Beijing Co Ltd
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological …
Full company profilePharmaron Beijing Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pharmaron Beijing Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.63B | 2.29B | 2.91B | 3.76B | 5.13B | 7.44B | 10.3B | 11.5B | 12.3B | 14.1B | 16.0B |
| Gross Profit | 474M | 772M | 950M | 1.33B | 1.92B | 2.68B | 3.76B | 4.12B | 4.18B | 4.91B | 5.27B |
| Operating Income | 190M | 263M | 393M | 631M | 1.32B | 1.91B | 1.69B | 1.85B | 2.10B | 2.22B | 2.35B |
| EBITDA | 281M | 504M | 641M | 928M | 1.32B | 1.85B | 2.23B | 2.43B | 2.58B | 3.29B | 2.25B |
| Net Income | 177M | 231M | 333M | 547M | 1.17B | 1.66B | 1.37B | 1.60B | 1.79B | 1.66B | 1.66B |
| EPS | 0.23 | 0.26 | 0.54 | 0.83 | 1.48 | 2.10 | 0.77 | 0.90 | 1.01 | 0.94 | 0.91 |
| Balance Sheet | |||||||||||
| Total Assets | 2.80B | 3.92B | 4.80B | 9.94B | 11.9B | 18.4B | 20.5B | 26.5B | 23.9B | 27.1B | 32.2B |
| Total Liabilities | 1.04B | 1.91B | 2.48B | 2.10B | 2.98B | 8.09B | 9.65B | 13.2B | 9.70B | 11.4B | 14.7B |
| Shareholders' Equity | 1.76B | 2.00B | 2.31B | 7.77B | 8.87B | 10.1B | 10.5B | 12.6B | 13.6B | 15.1B | 16.9B |
| Cash & Short-term Investments | 470M | 305M | 321M | 4.64B | 3.85B | 5.10B | 2.24B | 6.51B | 2.81B | 1.02B | 3.13B |
| Total Debt | 526M | 1.10B | 1.40B | 887M | 959M | 5.13B | 5.88B | 9.36B | 5.54B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 236M | 552M | 791M | 939M | 1.65B | 2.06B | 2.14B | 2.75B | 2.58B | 3.22B | - |
| Capital Expenditure | 1.06B | 935M | 641M | 755M | 1.32B | 2.09B | 2.95B | 2.87B | 2.04B | 2.67B | 2.94B |
| Free Cash Flow | -820M | -382M | 96.3M | 184M | 333M | -34.8M | -807M | -112M | 536M | 552M | -399M |
| Ratios | |||||||||||
| ROE | 10.0% | 11.6% | 14.4% | 7.0% | 13.2% | 16.4% | 13.0% | 12.8% | 13.2% | 11.0% | 9.8% |
| ROA | 6.3% | 5.9% | 6.9% | 5.5% | 9.8% | 9.0% | 6.7% | 6.0% | 7.5% | 6.1% | 5.2% |
| Net Profit Margin | 10.8% | 10.1% | 11.5% | 14.6% | 22.8% | 22.3% | 13.4% | 13.9% | 14.6% | 11.8% | 10.4% |
| Debt to Equity | 0.30x | 0.55x | 0.61x | 0.11x | 0.11x | 0.51x | 0.56x | 0.75x | 0.41x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pharmaron Beijing Co Ltd dividends
- Dividend yield
- 0.70%
- Forward dividend
- 0.20 CNY
- Payout ratio
- 31.9%
- Ex-dividend date
- Jul 7, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 531M | 0.30 | 31.9% |
| 2024 | CNY 542M | 0.31 | 30.2% |
| 2023 | CNY 445M | 0.25 | 27.8% |
| 2022 | CNY 405M | 0.23 | 29.4% |
| 2021 | CNY 238M | 0.30 | 14.3% |
| 2020 | CNY 119M | 0.15 | 10.2% |
| 2019 | CNY 72.2M | 0.11 | 13.2% |
| 2018 | CNY 74.6M | 0.12 | 22.4% |
| 2017 | CNY 60.6M | 0.07 | 26.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on Jul 27, 2023.
Who owns Pharmaron Beijing Co Ltd
- Insiders 35.18%
- Institutions 19.66%
- Public & others 45.16%
- Shares outstanding 1.48B
- Free float 1.25B
Pharmaron Beijing Co Ltd company profile
- Company name
- Pharmaron Beijing Co Ltd
- Ticker
- 300759.SHE
- ISIN
- CNE100003JW4
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 25,088
- Fiscal year end
- December
- Address
- Building 1, Beijing, China, 100176
- Phone
- 86 10 5733 0087
- Website
- pharmaron.com
About Pharmaron Beijing Co Ltd
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Pharmaron Beijing Co Ltd management
10- Dr. Boliang Lou Ph.D.Chairman & CEO · born 1963
- Mr. Xiaoqiang Lou EMBACo-Founder, President, COO & Executive Director · born 1968
- Mr. Shing Chung Li C.F.A., CPACFO, Secretary of the Board, Accounting Supervisor & Employee Representative Director · born 1978
- Dr. Hua Yang Ph.D.Chief Scientific Officer & Deputy Manager · born 1962
- Ms. Bei Zheng M.A.Executive VP & Executive Director · born 1967
- Dr. Connie Sun Ph.D.Senior VP & Global Head of Business Development of Small Molecules
- Ms. Celina Zhong M.B.A.Senior Vice President of Human Resources
- Ms. Katherine Lee M.B.A.Chief Business Officer
- Mr. Stephen LewintonSenior Vice President of UK Operations
- Dr. Jingqi HuangSenior Vice President of In Vivo Pharmacology